You are here: Industry Insights > acalabrutinib

News List

Calquence shows long-term efficacy and tolerability in MCL pharmatimes
December 08, 2020
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca's Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up ...
Leukemia & Lymphoma Society Launches Trial for Blood Cancer Patients with COVID-19 americanpharmaceuticalreview
September 15, 2020
The Leukemia & Lymphoma Society (LLS) is launching the first clinical trial for blood cancer patients at risk of death if infected with the COVID-19 virus.
Potential cytokine storm treatment identified for severe COVID-19 patients europeanpharmaceuticalreview
June 09, 2020
Treating COVID-19 patients with respiratory distress with acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor reduced inflammation and improved their breathing within three days.
Study identifies potential approach to treat patients with severe COVID-19 worldpharmanews
June 08, 2020
Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19.
AstraZeneca gets marketing permission for leukaemia drug in India expresspharma
March 13, 2020
AstraZeneca Pharma has received approval from India’s drug regulator to market Acalabrutinib 100mg capsules, medicine for the treatment of chronic lymphocytic leukaemia.
FDA grants Breakthrough Therapy Designation status for acalabrutinib europeanpharmaceuticalreview
August 02, 2017
It has been announced that the FDA has awarded AstraZeneca’s acalabrutinib product for MCL treatment Breakthrough Therapy Designation.